EUVIMEDEUVIMED entdecken
Crossref

Follow-up of bi-shRNA furin / GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in patients with advanced melanoma

Minal Barve, Joseph Kuhn, Jeffrey Lamont, Peter Beitsch, Luisa Manning, Beena O. Pappen, Padmasini Kumar, Gladice Wallraven, Neil Senzer, John Nemunaitis

Biomedical Genetics and Genomics · 2016

DOI: 10.15761/bgg.1000116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Genetics and Genomics, 2016. Verfasst von Minal Barve und 9 weiteren Autor:innen. Die Arbeit wurde bisher 8-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Barve, M., Kuhn, J., Lamont, J., Beitsch, P., Manning, L., Pappen, B. O., Kumar, P., Wallraven, G., Senzer, N., & Nemunaitis, J. (2016). Follow-up of bi-shRNA furin / GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in patients with advanced melanoma. Biomedical Genetics and Genomics. https://doi.org/10.15761/bgg.1000116

Vancouver

Barve M, Kuhn J, Lamont J, Beitsch P, Manning L, Pappen BO, et al. Follow-up of bi-shRNA furin / GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in patients with advanced melanoma. Biomedical Genetics and Genomics. 2016. doi:10.15761/bgg.1000116

BibTeX
@article{Barve2016,
  author = {Barve, Minal and Kuhn, Joseph and Lamont, Jeffrey and Beitsch, Peter and Manning, Luisa and Pappen, Beena O. and Kumar, Padmasini and Wallraven, Gladice and Senzer, Neil and Nemunaitis, John},
  title = {Follow-up of bi-shRNA furin / GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in patients with advanced melanoma},
  journal = {Biomedical Genetics and Genomics},
  year = {2016},
  doi = {10.15761/bgg.1000116}
}
Kostenlos starten →